Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1490705 | 0.90 | HTR1A (0.38) | KMT2AMEN1CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL1490895 | 0.86 | TLR7 (0.42) | KMT2ASMN1; SMN2 | |
| SCHEMBL1490250 | 0.85 | EPHX1 (0.39) | KMT2AMEN1LMNASMN1; SMN2MAPK1 | |
| SCHEMBL1490575 | 0.82 | BRD4 (0.35) | KMT2AMEN1HTTCYP2C19CYP2C9 | |
| SCHEMBL1490814 | 0.81 | BRD4 (0.32) | BRD4 | |
| SCHEMBL5635471 | 0.79 | TDP1 (0.36) | KMT2AMEN1HTTLMNASMN1; SMN2 | |
| SCHEMBL1490755 | 0.79 | ALDH1A1 (0.35) | KMT2AMEN1LMNA | |
| SCHEMBL5027913 | 0.78 | MEN1 (0.36) | KMT2AMEN1HTTCYP2C19CYP1A2 | |
| SCHEMBL4792410 | 0.77 | TDP1 (0.40) | KMT2AMEN1SMN1; SMN2GAARECQL | |
| SCHEMBL1490240 | 0.75 | HTR1A (0.41) | KMT2AMEN1CYP2C19CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598192-B2 | Hydroxylamine substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-12-03 | — | — | US | disclosed |
| US-7897767-B2 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090105295-A1 | HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090042925-A1 | OXIME SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105295-A1 | HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES | IL2, IL4, IFNG | KMT2A 1555/4885MEN1 3997/4885HTT 835/4885 |
| US-20090042925-A1 | OXIME SUBSTITUTED IMIDAZOQUINOLINES | IFNG, IL2, IRF3 | KMT2A 1931/4885MEN1 4500/4885HTT 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.